

A personalized blood test to help you and your health care provider find the right rheumatoid arthritis medication sooner


Rheumatoid arthritis (RA) affects everyone differently, therefore, each person should have a unique treatment approach.

There's a new way to select your medication for RA

RA is complex and affects every person differently. If left untreated, RA inflammation can damage multiple organs and increase your risk of heart disease.¹

The goal of treatment is to protect you from the potential damage caused by inflammation.

There are many medications that are used to treat RA. However, until PrismRA, health care providers did not have a tool to help them make more informed treatment decisions.



PrismRA is a personalized test based on your unique biology, that can help guide your health care provider when considering changes to your treatment.

Finding the right RA treatment for you

If your RA is flaring up and you're feeling unwell, your health care provider may suggest starting or increasing dosage of a medication called TNF inhibitor (TNFi) therapy.

TNFi therapies are commonly prescribed as a first-line biologic therapy.² While this drug type works for some, it is not a one-size-fits-all treatment. Every person is unique and may respond to medications differently.

With TNFi therapies, and the many other available medications, it can be hard to know which one is best for you.

Using the PrismRA result, your health care provider may decide to change the dosage of your current medication or start you on a new medication as the best approach to get your RA under control.

MOLECULAR SIGNATURE TEST

prism/RA

HEALTHCARE PROVIDER	CLINIC	PATIENT
Name: Robert Jones Requestor No: 00002022 Collection Date: 00-00-2022 Collection Time: 00:00 PM Specimen Received: 00-00-2022 Report Date: 00-00-2022	Clinic Name: Anytown Community Rheumatology Clinic Address: 1234 Main Street, Suite A1 Anytown, PA, 00000 Phone: 00-000-0000 Fax: 000-000-0000	Name: Jane Doe DOB: 00/00/0000 Sex: Female Weight: 150 Height: 5' 7" Patient Global Assessment: 65

PrismRA RESULT

<p>PrismRA TNFi Result:</p> <p style="text-align: center; font-weight: bold;">TNFi Inadequate Response Signature Not Detected</p> <p style="font-size: 0.8em;">This patient has a PrismRA Score of 9.2</p>	<p>Interpretive Criteria:</p> <div style="text-align: center; margin-bottom: 5px;"> <p style="font-weight: bold; font-size: 0.8em;">Patient may be likely to respond to a TNFi</p> </div> <p style="font-size: 0.7em;"><10.6: Patient does not have a detectable molecular signature of inadequate response to TNFi therapies</p>
---	---

PrismRA SCORE INTERPRETATION

A patient with a PrismRA Score <10.6 does not have a detectable molecular signature of inadequate response to TNFi therapies. The PrismRA result is reported on a continuous 1-25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies.

TEST DESCRIPTION

PrismRA is a molecular signature response classifier (MSRC) that uses gene expression features, clinical features and anti-cyclic citrullinated protein (anti-CCP) antibody to detect a signature of non-response to tumor necrosis factor- α inhibitors (TNFi) for patients with rheumatoid arthritis. PrismRA predicts the patient's likelihood of inadequately responding to all TNFi therapies. Total RNA was extracted from the blood sample and sequenced at Astery Genetics utilizing validated methods. Anti-CCP antibody measurements were performed at Scipher using validated methods. Final algorithmic analysis was performed at Scipher with PrismRA pipeline v1.1. Response is defined as achieving ACR50 at 6 months. The PrismRA result is reported on a continuous 1 to 25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies. However, a low score does not ensure a positive response to TNFi therapies.

COMMENTS

The PrismRA result is intended for informational purposes only and does not constitute a recommendation. Medical decisions should be made by your health care provider. This test was developed and its performance characteristics are certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified for use by laboratory personnel. ©2022 Scipher Medicine Corporation. All rights reserved. Scipher Medicine and PrismRA are trademarks of Scipher Medicine. All other trademarks are the property of their respective owners.

scipher

Scipher Medicine
8000 North Central Expressway
Dulles, VA 22029
800-913-1237

Astery Genetics
70000
Aliso Viejo, CA 92656
949-241-1237

Scipher Medicine, Inc.
10000
San Diego, CA 92121
619-594-1237

Early diagnosis and treatment in RA is associated with improved outcomes.⁷ Maximize your window of opportunity and see if PrismRA can help your health care provider find the right treatment for you.

PrismRA uses your unique biology

PrismRA is the first and only available blood test that analyzes your unique biology to tell you if TNFi therapies such as infliximab, adalimumab and etanercept, are less likely to work for you.^{3,4}

Getting on the correct therapy sooner helps:



decrease pain⁵




reduce your risk of joint damage⁵



improve your quality of life⁵

Patient's with moderate to severely active disease who were prescribed treatment based on their PrismRA result had clinical improvements that were more than 3 times higher than those whose treatment did not align with test results.⁶



Affordability

We are committed to making testing more accessible and affordable. Our team will work directly with your insurance provider and health care provider to try to obtain coverage while minimizing any financial burden.



Patient-Friendly Billing Policy

- Scipher is committed to never surprise bill any patient
- The majority of patients tested pay less than \$75
- If we estimate your out-of-pocket expense is greater than \$75, we will reach out to you directly to discuss testing



Affordable Payment Plans

- We offer payment plans and financial assistance to those that qualify to ensure all patients have equal access to PrismRA

Ask Your Health Care Provider
if the PrismRA Test can help
guide your medical care.

Please call us at **(855) 724-7437**
or email **Billing@Scipher.com**

1. Arthritis Foundation: Rheumatoid Arthritis and Heart Disease. www.arthritis.org/health-wellness/about-arthritis/related-conditions/other-diseases/rheumatoid-arthritis-heart-disease. Accessed 4/22/22. 2. Jin, Y., Desai, R.J., Liu, J. et al. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. *Arthritis Res Ther* 19, 159 (2017). 3. Mellors T, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. *Network and Systems Medicine* 2020; 3(1):1–14. 4. Cohen, S., Wells, A.F., Curtis, J.R. et al. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- α Inhibitors: The NETWORK-004 Prospective Observational Study. *Rheumatol Ther* 8, 1159–1176 (2021). 5. Creaky Joints: RA Testing Patient Guideline. https://creakyjoints.org/www/wp-content/uploads/CreakyJoints_RA_Testing_Patient_Guideline.pdf. Accessed 6/1/22. 6. Strand V, Cohen SB, Curtis JR, et al. Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- α inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis. *Expert Rev Mol Diagn.* 2022;22(1):101-109. 7. Fraenkel, L., et al. (2021), American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res*, 73: 924-939.